Champions Oncology (CSBR) stock price, chart and financials
Price chart
Financials
- Revenue (quarter)
- $15.2M
- Gross margin
- 49.82%
- Net income (quarter)
- −$426,000.00
- Net margin
- −1.87%
- Return on equity
- −30.67%
- Book value per share
- $0.28
- Price to book
- 15.29
- Debt to assets
- 86.60%
Company profile
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.
Frequently asked questions
Is Champions Oncology (CSBR) profitable?
No. Champions Oncology reported a net loss of $1.1M over the trailing twelve months.
How much revenue does Champions Oncology (CSBR) make?
Champions Oncology generated $60.7M in revenue over the trailing twelve months, up 8.84% year over year.
How do I buy stock in Champions Oncology (CSBR)?
CSBR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.